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According to population statistics in Japan, approximately 3,800 women die of ovarian
cancer annually, and approximately 6,000 are affected by this disease. Ovarian cancer is
referred to as a “silent tumor”, since patients have few subjective symptoms and by the time
symptoms are observed, the cancer has progressed to Stage III or IV in about half of the
patients. The basic treatment for advanced epithelial ovarian cancer is to remove as much
of the tumor as possible, and subsequently to perform anticancer therapy using drugs such
as cisplatin, carboplatin and paclitaxel, all of which have been shown to be effective for epi-
thelial ovarian cancer. However, the 5-year survival rate in advanced ovarian cancer patients
is still only about 20%, and a treatment that leads to long-term survival has yet to be devel-
oped. Here, we review the available treatments for ovarian cancer, and present the results
of high-dose chemotherapy (HDC) performed in our hospital for recurrent and refractory
ovarian cancer.
Key words: recurrent/refractory ovarian cancer, high-dose chemotherapy, hematopoietic stem cell
transplantation, treatment
I. Introduction
Between 1984 and 1995, high-dose chemotherapy
(HDC) based mainly on platinum compounds (cisplatin and
carboplatin) with autologous bone marrow transplantation
or peripheral blood stem cell transplantation were performed
with the goal of achieving long-term survival in patients
with advanced and refractory epithelial ovarian cancer [27,
28, 37, 38]. This approach was taken based on the results of
in vitro studies [2, 3], in which a higher dose of platinum
compounds was shown to be likely to kill more ovarian can-
cer cells [15, 20, 30]. However, subsequent studies suggest-
ed that the dose of platinum compounds is not necessarily
correlated with treatment effects, including a randomized
study performed in 1995 by the Gynecologic Oncology
Group (GOG) in the U.S. in patients with ovarian cancer at
Stage III and IV. In this study, Group A received 8 courses
of 50 mg/m2 cisplatin (CDDP) and 500 mg/m2 cyclophos-
phamide (CPM), and Group B received 4 courses of 100
mg/m2 CDDP and 1000 mg/m2 CPM; therefore, the total
doses of the two groups were the same. In groups A and B,
respectively, the response rates were 60% and 55%, the 4-
year survival rates were 20% and 20%, the mean survival
times were 19.5 and 21.3 months, and the mean progression-
free survival times were 12.1 and 14.3 months. Since there
were no significant differences between the patients in the
two groups, these results indicate that the dose intensity is
not correlated with chemotherapeutic effects [21]. Similar
results have been obtained in subsequent randomized studies
[8, 14, 16], and it is now generally thought that doubling the
recommended dose does not improve chemotherapeutic
effects in a multi-drug regimen including platinum com-
pounds.
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II.　Combination Chemotherapy with
Hematopoietic Stem Cell Transplantation
for Advanced Epithelial Ovarian Cancer
More than 15 years have passed since the introduction
of HDC for advanced epithelial ovarian cancer, and HDC is
now performed more safely and effectively due to hemato-
poietic stem cell support [24]. Therefore, it has become pos-
sible to increase the dose intensity in HDC compared with
doses used in conventional chemotherapy, leading to expec-
tations of improved progression-free survival (PFS) and
overall survival (OS) [5, 12, 19, 25, 26, 39–42]. However,
the results of randomized studies comparing HDC with con-
ventional chemotherapy show that the complete remission
period is short and the long-term survival rate is only 10–
20% in HDC, although an apparent high responsiveness and
high response rate are observed at the beginning of treatment
[5, 25, 26, 39, 41]. The conventional regimen in HDC is
mainly based on platinum compounds: combined treatment
of 100–150 mg/m2 CDDP and 800–1600 mg/m2 CBDCA
(fundamental agents) with CPM, etoposide and thiotepa is
generally performed.
We initially performed a pilot study to observe long-
term prognosis in 105 patients with advanced and recurrent
ovarian cancer, using 1–2 courses of 100–150 mg/m2 CDDP,
100 mg/m2 adriamycin (ADM) and 1600–2400 mg/m2 CPM;
or 900–1600 mg/m2 CBDCA and 1500–3000 mg/m2 CPM.
In this study, the respective 5-year PFS and OS rates were
35.7% and 58.1% in Stage III patients, 22.6% and 33.7%
in Stage IV patients, and 31.0% and 37.5% in recurrent
patients. Furthermore, among 65 Stage III and IV patients,
the respective rates of PFS and OS were 51.5% and 74.3% in
patients with a residual tumor diameter of not more than 5
mm, 0% and 30.8% in patients with a diameter of 5 mm to
20 mm, and 16.7% and 22.6% in patients with a tumor
diameter of not less than 20 mm [37].
We recently showed that immunohistochemical expres-
sion of mutant p53 protein is decreased by HDC in ovarian
cancer tissues, and that the level of p53 immuno-expression
is related to the chemotherapeutic effect (Figs. 1, 2) [11].
The p53 tumor suppressor gene is closely associated with
DNA repair and apoptosis, and mutant p53 accumulates in
tumor cells of advanced refractory ovarian cancer, causing
the cells to proliferate. In cancer cells sensitive to platinum-
based chemotherapy, wild-type p53 induces apoptosis and
repair of damaged DNA, whereas chemotherapy-resistant
cancer cells include a mutant p53 that cannot induce apopto-
sis of cancer cells and does not inhibit cancer cell growth
[36]. In advanced refractory ovarian cancer treated with
platinum-based HDC, most p53 protein-positive tumor cells
underwent apoptosis, and p53 expression was suppressed in
one tumor that recurred after HDC and was removed in a
second reduction surgery [36]. In contrast, p53 protein-posi-
tive tumor cell growth was not suppressed in conventional
chemotherapy (CONV) using a normal dose of cisplatin, and
high p53 expression was found in a tumor that recurred after
Fig. 1. HDC in a case of ovarian endometrioid adenocarcinoma. Mutant p53 immuno-expression was observed before HDC (a) but not after
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CONV and was removed in a second reduction surgery [36].
Legros et al. performed a pilot HDC study using mel-
phalan (140 mg/m2), or CBDCA (400 mg/m2 on Days 1–4)
and CPM (1600 mg/m2 on Days 1–4) in 53 Stage III and IV
patients, and found 5-year PFC and OS rates of 23.6% and
59.9%, respectively [19]. Of particular importance, a com-
plete pathological response was confirmed in a second-look
operation in 19 of 24 survivors. Furthermore, Ledermann et
al. (in the European group study) reported that the median
OS is 59 months in Stage III patients and 40 months in Stage
IV after HDC [18]. All these results indicate a favorable
long-term prognosis following use of HDC, compared with
conventional chemotherapy.
III.　Use of HDC for Recurrent and Refractory 
Ovarian Cancer at Tokai University Hospital
HDC combined with autologous stem cell transplanta-
tion has been performed for advanced epithelial ovarian
cancer at our hospital since 1984 [27, 28, 37, 38]. Here,
we present a retrospective study of the long-term effects of
HDC in patients with recurrent and refractory ovarian cancer
who were treated until 1996. The subjects were 20 epithelial
ovarian cancer patients in whom the lesion disappeared and
remission was attained at initial treatment but recurrence
was then observed, in whom a poor response occurred and
tumor markers did not become negative after initial treat-
ment, who showed positive laparoscopic findings after ini-
tial treatment, or who had no response to initial treatment
and are refractory to HDC. In 18 of these 20 patients, we per-
formed a second-look operation before HDC to observe the
level of recurrence in the abdominal cavity, and conducted
tumor reduction surgery (Fig. 3, Table 1). Six of the 20
patients have survived and 14 have died; the Kaplan-Meier
survival curve is shown in Figure 4. In 9 patients, tumor
reduction surgery resulted in the remaining tumor having a
diameter of not more than 5 mm before HDC, and 5 of
these 9 patients showed long-term survival. In contrast, in 6
patients the residual tumor diameter was 20 mm or greater,
and all of these patients died from 4 to 32 months after HDC
treatment (mean survival period: 16 months). These data
were partly the basis of the significant difference (p0.05) in
the survival curves of patients with a residual tumor diame-
ter of 5 mm or greater (n11) and those with a residual
diameter of less than 5 mm (n9) (Fig. 4).
A significant difference (p0.0238) was found in the
platinum-free interval (PFI) (duration from previous HDC to
second HDC) between the 6 surviving patients (range: 26–
44 months, mean: 35.5 months) and the 14 patients who died
(range: 4–48 months, mean: 20.1 months) (Fig. 5). Also, the
13 recurrent patients who initially showed remission had a
higher survival rate (a 5-year survival rate of 53.8%) com-
pared to the 7 refractory cases (a 3-year survival rate of
14.3%) (Table 2). Concerning the histology of the ovarian
cancer, 6 of the 7 refractory cases had clear cell carcinoma or
mucinous adenocarcinoma.
Fig. 2. Conventional chemotherapy (CONV) in a case of ovarian serous adenocarcinoma. No significant mutant p53 expression was observed
before CONV (a) and after CONV (b) (50).Muramatsu et al. 64
After administration of a HDC regimen of 2400 mg/m2
CPM, 100 mg/m2 ADM and 150 mg/m2 CDDP, autologous
bone marrow transplantation was performed. In our support-
ive care protocol, patients with hemoglobin 8.0 g/dl or
platelet levels 2.0104/l were indicated for transfusions of
15Gy-irradiated red blood cells or platelets, respectively. If
the patients became febrile, broad-spectrum antibiotics were
administered. Intravenous administration of G-CSF con-
tinued until confirmation of bone marrow recovery to 1.0
104/l white blood cells. Peripheral leukocyte count was
continuously less than 100/l for 4 days, and 17 days were
required for neutrophils to recover to at least 1500/l and
13 days for platelets to reach at least 50,000/l (Table 3).
Fever (not less than 38C) accompanied by leucopenia was
observed for a mean period of 2.5 days. Overall, the results
indicated that removal of as much as possible of the tumor is
favorable (if possible, the residual tumor diameter should be
less than 5 mm) for attainment of high treatment efficacy
in HDC for recurrent and refractory ovarian cancer as a
second-line chemotherapy. In addition, a long PFI from
the previous treatment may be beneficial.
Fig. 3. Normal and/or high dose chemotherapy in patients with
advanced ovarian cancer.
Table 1. Characteristics of 20 recurrent and refractory epithelial ovarian cancer patients with HDC who were treated at Tokai University
Hospital
Case Age
Primary surgery Secondary surgery
2nd HDC-regimen No. of courses Survival time 
[months] stage histology residual tumor (mm)
1. 56 IV S Micro CAP 1 57
2. 45 IIIb S Micro CAP 2 140
3. 29 Ia M 20 CAP 2 4†
4. 47 IIIc S 20 CAP 2 21†
5. 48 IIIc S 20 CAP 2 32†
6. 56 IIIc M — CAP 2 156†
7. 49 IIIc S 20 CAP 2 17†
8. 45 Ic C 20 CAPVP16 2 12†
9. 52 IIIc E Micro CBDCACPM* 1 60
10. 46 IIIb E Micro CBDCACPM* 1 79
11. 43 IIIb S 20 CBDCACPM* 1 79
12. 63 IIIb S Micro CBDCACPM* 1 102
13. 52 IIIb S Micro CBDCACPM* 1 34†
14. 53 IIIc S Micro CBDCACPM* 1 89†
15. 37 IIc C 20 CBDCACPM* 2 22†
16. 38 Ia M 5 CBDCACPM* 2 12†
17. 50 IIIc S 5 CBDCA#VP16 1 17†
18. 63 IV S 20 CBDCA#VP16 1 25†
19. 42 Ic C — CBDCA#VP16 2 27†
20. 41 Ic S 20 CBDCAVP16Tes 1 6†
S: serous, M: mucinous, C: clear cell, E: endometrioid.
CAP: cyclophosphamide (CPM) 500–2400 mg/m2adriamycin 50–100 mg/m2cisplatin 100–150 mg/m2. VP16: 600–900 mg/m2, carboplatin
(CBDCA): 750–1500 mg/m2, CPM*: 1500–3000 mg/m2, CBDCA#: 600–750 mg/m2, Tes: tespamin 600 mg/m2, †: dead patients, —: non second-
ary surgery.
Table 2. Survival after HDC in recurrent and refractory ovarian cancer patients
No. of survivors (survival %) after HDC
1 3 5 7 (year)
Recurrent patients (n13) 13 (100) 10 (76.9) 7 (53.8) 7 (53.8)
Refractory patients (n7) 3 (42.9) 1 (14.3) 1 (14.3) 1 (14.3)High Dose Chemotherapy for Ovarian Cancer 65
IV.　New Treatment Strategy
The history of chemotherapy for ovarian cancer
includes the introduction of a platinum compound (cisplatin,
CDDP) in 1970, and since then treatment based mainly on
this compound has been thought to be most effective [13,
17]. However, nephrotoxicity and peripheral nerve disorder
are dose-limiting factors in cisplatin therapy, and severe
visual disturbance may also occur [29], thereby requiring
careful attention to side effects with use of cisplatin.
Carboplatin (CBDCA), a second-generation platinum com-
pound, was subsequently developed; the anti-tumor effect of
CBDCA is almost equal to that of CDDP [1, 7], and the
potency of CBDCA is 4 times lower than that of CDDP
[32]. Furthermore, unlike CDDP, CBDCA induces only very
mild nephrotoxicity and peripheral nerve disorder, and its
limiting side effect of bone marrow suppression can be
alleviated by reducing the dose according to the degree of
renal dysfunction in individual patients [6].
In the late 1980s, drug tolerance toward platinum com-
pounds was identified as a significant prognostic factor, and
expectations were placed on discovery of new anticancer
agents. Among these, paclitaxel (PTX) was shown to have
no cross-tolerance with platinum compounds, suggesting
that it could be a new agent for treatment of ovarian cancer.
PTX was approved in the US and Europe in 1992, and the
optimal dose of PTX has subsequently been investigated [4,
10, 23]. Many clinical studies based mainly on PTX have
been conducted [22, 33–35], and combination chemotherapy
of PTX and CBDCA is now common as the “gold standard”
for epithelial ovarian cancer treatment. In Japan, the deci-
sion to allow coverage of PTX in the health insurance sys-
tem from December 1997 has allowed the drug to be used
for general treatment of ovarian cancer patients.
In 2004, Japan Society of Gynecologic Oncology
issued Ovarian Cancer Treatment Guidelines [31]. The main
purposes of these guidelines are to define appropriate treat-
ments for ovarian cancer, to reduce the differences in treat-
ments levels among facilities, and to establish safer and
more effective treatments. Combination therapy of PTX
and CBDCA may be the optimal regimen for chemotherapy
based on the results of many previous studies [9, 22, 33–35];
Fig. 4. Correlation between survival and residual tumor size.
Fig. 5. Correlation between survival and platinum-free interval.
Table 3. Days required for recovery of peripheral blood count
after HDCa in 20 recurrent and refractory ovarian cancer
patients
Median days (range)
Leukocyte count under 100/l 4 (0–9)
Neutrophil count over 500/l 13.5b (10–19)
Neutrophil count over 1,500/l 17b (11–46)
Platelet count over 50,000/l 13b (0–21)
Neutropenic fever up over 38C 2.5 (0–7)
a HDC regimen: cyclophosphmice 2400 mg/m2+adriamycin 100 mg/m2
cisplatin 150 mg/m2.
b Days after autologous bone marrow transplantation.Muramatsu et al. 66
however, when administration of 175–180 mg/m2 PTX
and AUC5-6 CBDCA was started (every 21–28 days, 6–9
courses) in our facility, approximately 30% of the patients
showed strong bone marrow suppression. The decreases of
leukocytes and platelets by 2–3 grades sometimes persisted,
requiring reduction of the doses of PTX and carboplatin, and
consequently decreasing treatment efficacy and quality in
some cases. In this context, it is important to note that most
data cited in the guidelines [31] were obtained in European
and American patients. In particular, optimal doses for Japa-
nese women have not been determined and no recommended
treatment has been established for recurrent refractory ovari-
an cancer, although anticancer agents for salvage chemo-
therapy are listed in the guidelines. Therefore, we suggest
that further randomized studies of treatment for recurrent
ovarian cancer be conducted.
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